高级检索
当前位置: 首页 > 详情页

Extracellular fibrinogen-binding protein released by intracellular Staphylococcus aureus suppresses host immunity by targeting TRAF3

文献详情

资源类型:
Pubmed体系:

收录情况: ◇ 自然指数

机构: [1]National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, ThirdMilitary Medical University, Chongqing 400038, China [2]Department of Basic Courses, NCO School, Third Military Medical University, Shijiazhuang 050081,China [3]College ofMedicine, Southwest JiaotongUniversity,Chengdu 610083,China [4]Institute of Biopharmaceutical Research,WestChinaHospital, SichuanUniversity, Chengdu, Sichuan 610041, China [5]Department of Immunology, School of Basic Medical Sciences, Shanghai Institute of Infectious Disease andBiosecurity & Shanghai Public Health Clinical Center, Fudan University, Shanghai 200032, China
出处:

摘要:
Many pathogens secrete effectors to hijack intracellular signaling regulators in host immune cells to promote pathogenesis. However, the pathogenesis of Staphylococcus aureus secretory effectors within host cells is unclear. Here, we report that Staphylococcus aureus secretes extracellular fibrinogen-binding protein (Efb) into the cytoplasm of macrophages to suppress host immunity. Mechanistically, RING finger protein 114, a host E3 ligase, mediates K27-linked ubiquitination of Efb at lysine 71, which facilitates the recruitment of tumor necrosis factor receptor associated factor (TRAF) 3. The binding of Efb to TRAF3 disrupts the formation of the TRAF3/TRAF2/cIAP1 (cellular-inhibitor-of-apoptosis-1) complex, which mediates K48-ubiquitination of TRAF3 to promote degradation, resulting in suppression of the inflammatory signaling cascade. Additionally, the Efb K71R mutant loses the ability to inhibit inflammation and exhibits decreased pathogenicity. Therefore, our findings identify an unrecognized mechanism of Staphylococcus aureus to suppress host defense, which may be a promising target for developing effective anti-Staphylococcus aureus immunomodulators.© 2022. The Author(s).

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 1 区 综合性期刊
小类 | 1 区 综合性期刊
最新[2023]版:
大类 | 1 区 综合性期刊
小类 | 1 区 综合性期刊
第一作者:
第一作者机构: [1]National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, ThirdMilitary Medical University, Chongqing 400038, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43377 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号